Oxford Immunotec (OXFD) Tops Q4 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Oxford Immunotec Reports Fourth Quarter and Full Year 2016 Financial Results
February 28, 2017 4:06 PM ESTFourth quarter revenue of $23.7 million, an increase of 41% compared to prior year periodFourth quarter Tuberculosis revenue of $20.4 million, an increase of 22% compared to prior year periodFourth quarter Tick-borne disease and other revenue of $3.3 millionFull year 2016 revenue of $86.1 million increased 37% compared to prior yearCompleted $40 million debt financing made up of term loan and revolving line of creditAnnounces guidance for full year 2017 revenue of between $102 and $105 million
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:... More
